GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Price-to-Free-Cash-Flow

Paratek Pharmaceuticals (FRA:N4CN) Price-to-Free-Cash-Flow : N/A (As of Jun. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-06-11), Paratek Pharmaceuticals's share price is €2.024. Paratek Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.42. Hence, Paratek Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Paratek Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Paratek Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 13.78. The lowest was 12.58. And the median was 13.18.

FRA:N4CN's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.56
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Paratek Pharmaceuticals's Free Cash Flow per Share for the three months ended in Jun. 2023 was €-0.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.42.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 32.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 19.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 17.90% per year.

During the past 13 years, Paratek Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 79.60% per year. The lowest was -15.20% per year. And the median was 18.15% per year.


Paratek Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Paratek Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Price-to-Free-Cash-Flow Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Paratek Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Paratek Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Paratek Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Paratek Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.024/-0.415
=N/A

Paratek Pharmaceuticals's Share Price of today is €2.024.
Paratek Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Paratek Pharmaceuticals  (FRA:N4CN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Paratek Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines